Brinzolamide--A New Topical Carbonic Anhydrase Inhibitor for Glaucoma
Brinzolamide (Azopt - Alcon), a thieno-thiazine-6-sulfonamide carbonic anhydrase inhibitor, has been approved by the FDA in a 1% ophthalmic suspension for treatment of elevated intraocular pressure due to ocular hypertension or open-angle glaucoma. Brinzolamide is the second FDA-approved topical carbonic anhydrase inhibitor. Dorzolamide (Trusopt) was approved earlier (Medical Letter, 37:76, 1995)....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Brinzolamide--A New Topical Carbonic Anhydrase Inhibitor for Glaucoma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1036
Article Code: 1036c
Date: September 25, 1998
Volume: 40
Pages: 95-96
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1036
Article Code: 1036c
Date: September 25, 1998
Volume: 40
Pages: 95-96
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)